Disorders of tyrosine catabolism

Molecular Genetics and Metabolism

Volumn 88, Issue 2, 2006, Pages 103-106

  Held, Patrice K ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIS TRANS ISOMERASE; MALEYLACETOACETATE ISOMERASE; TYROSINE;

ALKAPTONURIA; ANIMAL; ARTICLE; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; TYROSINEMIA;

ALKAPTONURIA; ANIMALS; CIS-TRANS-ISOMERASES; HUMANS; TYROSINE; TYROSINEMIAS;

EID: 33745320018     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.04.002     Document Type: Article

References (23)

1. B.N. La Du, Alkaptonuria, in: C.R. Scriver, A.L. Beaudet, W. Sly, D. Valle (Eds.), The Metabolic and Molecular Basis of Inherited Disease, MacGraw-Hill, New York, 1995, pp. 1371-1386.
2. G.A. Mitchell, M. Grompe, M. Lambert, R.M. Tanguay, Hypertyrosinemia, in: C.R. Scriver, A.L. Beaudet, W. Sly, D. Valle (Eds.), The Metabolic Basis of Inherited Disease, MacGraw-Hill,NewYork, 1999, pp. 1077-1106.
3. A. Fois, P. Borgogni, M. Cioni, M. Molinelli, R. Frezzotti, A.M. Bardelli, G. Lasorella, L. Barberi, P. Durand, M. Di Rocco, C. Romano,R. Parini, C. Corbetta,M.Giovannini, E. Riva, N. Balato, R. Sartorio, F. Mollica, E. Zammarchi,M.L. Battini, Presentation of the data of the Italian registry for oculocutaneous tyrosinemia, J. Inherit. Metab. Dis. 9 (1986) 262-268.
4. R. Cerone, E. Holme, M.C. Schiaffino, U. Caruso, L. Maritano, C. Romano, Tyrosinemia type III: diagnosis and ten-year follow-up, Acta Paediatr. 86 (1997) 1013-1015.
5. F. Endo, H. Katoch, S. Yamamoto, I. Matsuda, A murine model for type III tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic acid dioxygenase enzyme protein in a novel mouse strain with hypertyrosinemia, Am. J. Hum. Genet. 48 (1991) 704-709.
6. A.E. Garrod, The incidence of alkaptonuria: a study in chemical individuality, Lancet 2 (1902) 1616-1620.
7. B.N. LaDu, V.G. Zannoni, L. Laster, J.E. Seegmiller, The nature of the defect in tyrosinemetabolismin alkaptonuria, J. Biol. Chem. (1958) 230.
8. V.G. Zannoni, N. Lomtevas, S. Goldfinger, Oxidation of homogentisic acid to ochronotic pigment in connective tissue, Biochim. Biophys. Acta 177 (1969) 94-105.
9. P. Suwannarat, K.O'Brien, M.B. Perry, N. Sebring, I. Bernardini, M.I. Kaiser-Kupfer, B.I. Rubin, E. Tsilou, L.H. Gerber, W.A. Gahl, Use of nitisinone in patients with alkaptonuria, Metabolism 54 (2005) 719- 728.
10. J.M. Fernandez-Canon,M.W.Baetscher, M.Finegold, T. Burlingame, K.M. Gibson, M. Grompe, Maleylacetoacetate isomerase (MAAI/ GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism, Mol. Cell. Biol. 22 (2002) 4943-4951.
11. J.M. Fernandez-Canon, M.A. Penalva, Molecular characterization of a gene encoding a homogentisate dioxygenase from Aspergillus nidulans and identification of its human and plant homologues, J. Biol. Chem. 270 (1995) 21199-21205.
12. P. Russo, S. O'Regan, Visceral pathology of hereditary tyrosinemia type I, Am. J. Hum. Genet. 47 (1990) 317-324.
13. A.G. Weinberg, C.E. Mize, H.G. Worthen, The occurrence of hepatoma in the chronic form of hereditary tyrosinemia, J. Pediatr. 88 (1976) 434-438.
14. M. St-Louis, R.M. Tanguay, Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview, Hum. Mutat. 9 (1997) 291-299.
15. D. Phaneuf, Y. Labelle, D. Berube, K. Arden, W. Cavenee, R. Gagne, R.M. Tanguay, Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15, Am. J. Hum. Genet. 48 (1991) 525-535.
16. S. Sassa, A. Kappas, Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of deltaaminolevulinate synthase in liver, Trans. Assoc. Am. Physicians 95 (1982) 42-52.
17. M.S. Sun, S. Hattori, S. Kubo, H. Awata, I. Matsuda, F. Endo, A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice, J. Am. Soc. Nephrol. 11 (2000) 291- 300.
18. S. Lindstedt, E. Holme, E.A. Lock, O. Hjalmarson, B. Strandvik, Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase, Lancet 340 (1992) 813-817.
19. E. Holme, S. Lindstedt, Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione), J.Inherit. Metab. Dis. 21 (1998) 507-517.
20. F.J. van Spronsen, C.M. Bijleveld, B.T. van Maldegem, F.A. Wijburg, Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro-methylbenzoyl)-1, 3-cyclohexanedione treatment, J. Pediatr. Gastroenterol. Nutr. 40 (2005) 90-93.
21. C. Dionisi-Vici, C. Boglino, M. Marcellini, Tyrosinemia type I with early metastatic hepatocellular carcinoma: combined treatment with NTBC, chemotherapy and surgical mass removal, J. Inherit. Metab. Dis. 20 (1997) 3.
22. N. Mohan, P. McKiernan, M.A. Preece, A. Green, J. Buckels, A.D. Mayer, D.A. Kelly, Indications and outcome of liver transplantation in tyrosinaemia type 1, Eur. J. Pediatr. 158 (Suppl. 2) (1999) S49-S54.
23. E.A. Kvittingen, H. Rootwelt, P. Brandtzaeg, A. Bergan, R. Berger, Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect, J. Clin. Invest. 91 (1993) 1816-1821.